Fennec Resubmits Pedmark NDA To FDA

Fennec Pharmaceuticals Inc. (FENC) said on Thursday that it has resubmitted its New Drug Application for Pedmark to the FDA.

Pedmark is a formulation of sodium thiosulfate, proposed for the prevention of platinum-induced ototoxicity in pediatric patients, especially cancer patients who have undergone chemotherapy, from one month to below 18 years of age group with localized, non-metastatic, solid tumors.

Pedmark has already received Breakthrough Therapy and Fast Track Designation by the FDA in 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT